Anthony is a co-founder of enGene and has served in various capacities since enGene’s inception, including as President and Chief Executive Officer. He is currently Chief Scientific Officer, overseeing the development and application of enGene’s novel and proprietary Dually Derivatized Oligochitosan (DDX) platform. He has co-authored numerous book chapters, review articles and peer-reviewed journals, and is a named inventor on numerous patents in the areas of gene therapy and polymer chemistry. Anthony holds a B.Sc. from University of British Columbia and a Ph.D. in Physiology from the Tulane University School of Medicine.

• 

  Co-Founder in enGene

  Mainstreaming Gene Therapy

• 

  Chief Scientific Officer (CSO) in enGene

  Mainstreaming Gene Therapy